Why Lexicon Pharmaceuticals (LXRX) Is Back In The Spotlight

Lexicon Pharmaceuticals (LXRX) has drawn fresh attention after new SOLOIST-WHF Phase 3 post hoc data on sotagliflozin were shared at ESC Congress 2026. The findings reinforce consistent efficacy and safety across baseline blood pressure in high risk heart failure patients.

Despite the new SOLOIST-WHF data, Lexicon Pharmaceuticals’ share price has softened in the very short term, with a 1-day share price return of 1.75% and a 7-day share price return of 3.85%. However, a 90-day share price return of 21.62% and a year-to-date share price return of 97.37%, alongside a 1-year total shareholder return of 100.89%, suggest momentum has built over the past year even though the 5-year total shareholder return is down 52.83%.

Scan beyond Lexicon Pharmaceuticals and size up other biopharma stocks with fresh clinical data or product momentum using our hand picked 19 high quality undiscovered gems.

After a sharp year to date rise, then a recent pullback on fresh SOLOIST-WHF data, it is worth asking how much of Lexicon Pharmaceuticals’ move reflects business fundamentals rather than a swing in sentiment, and what the current price implies.

Most Popular Narrative: 40.3% Undervalued

The most followed narrative for Lexicon Pharmaceuticals compares a fair value of $3.77 to the last close of $2.25 and frames a wide gap that hinges on ambitious revenue and profitability assumptions over the coming years.

Lexicon Pharmaceuticals is focused on advancing its pipeline of novel medicines, including progressing pilavapadin into pivotal trials as a first novel oral non-opioid treatment for diabetic peripheral neuropathic pain in over two decades. This could significantly impact future revenue and market share.

The company is developing LX9851, a first-in-class oral ACSL5 inhibitor for obesity and related cardiometabolic disorders, with promising preclinical data. This could open new revenue streams and target high-demand markets once the IND is submitted in 2025.

Read the complete narrative.

Curious what justifies a higher fair value for an unprofitable company like Lexicon Pharmaceuticals? The narrative leans on strong top line forecasts, a sharp margin swing and a rich future earnings multiple. Want to see how those pieces fit together and what assumptions really sit behind $3.77?

Result: Fair Value of $3.77 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Lexicon Pharmaceuticals still faces real execution risks, including reliance on partners like Novo Nordisk and Viatris, as well as ongoing losses that could require further funding or dilution.

Find out about the key risks to this Lexicon Pharmaceuticals narrative.

Another View on Lexicon Pharmaceuticals Valuation

The earlier narrative leans on a fair value of $3.77 that treats Lexicon Pharmaceuticals as undervalued. On simple pricing, however, the picture looks very different. The stock trades on a P/S of 24.1x, compared with an industry average of 5.1x and a fair ratio of 8.9x. This points to a rich valuation and less room for error if the growth story slips.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages in the Lexicon Pharmaceuticals story so far. If you want to move fast and build your own view, start with the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Lexicon Pharmaceuticals?

If you only watch Lexicon Pharmaceuticals, you could miss other stocks that better fit your goals. Use the Simply Wall St Screener to compare fresh ideas side by side.

• Target potential mispricing by scanning a focused set of quality companies trading below fair value using the 45 high quality undervalued stocks.
• Prioritise resilience by zeroing in on companies with stronger balance sheets and fundamentals through the list of solid balance sheet and fundamentals (52 results).
• Reduce surprises by focusing on companies with lower measured risk profiles using the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com